Amanda Winters - School of Medicine



CURRICULUM VITAE

Amanda Catherine Winters

Personal Information:

Assistant Professor, Pediatric Hematology/Oncology/BMT

Children’s Hospital Colorado Center for Cancer and Blood Disorders

13123 E 16th Avenue, B115

Aurora, CO 80045

amanda.winters@

Education:

2000-2004 B.S. University of Southern Mississippi, Hattiesburg, MS.

2004-2011 M.D. Tulane University School of Medicine, New Orleans, LA.

2006-2009 Ph.D. Tulane University School of Medicine, New Orleans, LA.

2011-2014 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

- Pediatric Residency

2014-2017 Children’s Hospital Colorado, Aurora, CO

- Pediatric Hematology and Oncology Fellowship

2017-2018 - 4th Year Fellowship in Malignant Hematology

Honors and Awards:

2003 Barry Goldwater Scholarship recipient

2004 Phi Kappa Phi Graduate Fellowship recipient

2010 Elected member of Alpha Omega Alpha (AOA) Medical Honor Society

2018 Chosen as one of 100 trainees to attend the ASCO/AACR Methods in Clinical Cancer Research

Workshop (Vail, CO)

Professional Affiliations:

2011-curr American Academy of Pediatrics (member)

2014-curr Children’s Oncology Group (COG) member

2016-curr American Society of Pediatric Hematology/Oncology (ASPHO) member

2016-curr American Society of Hematology (member)

Licensure and Board Certification:

October 2014 American Board of Pediatrics certification, General Pediatrics

April 2019 American Board of Pediatrics certification, Pediatric Hematology/Oncology

Research Experience:

Summer 2003 Research Intern, St. Jude Children’s Research Hospital, Memphis, TN

▪ identification of novel biomarkers for pediatric leukemias using capillary-scale reverse-phase HPLC and MALDI-TOF mass spectrometry

2006-2009 Graduate Student Researcher, laboratory of Charles Hemenway, M.D., Ph.D., Loyola University Medical Center, Maywood, IL

▪ study of molecular aberrations contributing to mixed-lineage leukemia (MLL)

▪ in vitro testing of a novel peptide-based therapy for MLL

▪ training in cell culture, Western blotting/IP, immunofluorescence microscopy, flow cytometry, quantitative PCR, yeast/bacteria-based cloning

2015-curr Clinical Research Fellow, laboratory of Craig Jordan, Ph.D., Univ of Colorado Denver

▪ study of AML stem cell metabolism, MRD evaluations, and selection of chemo-resistant subpopulations

▪ identification and pre-clinical testing of novel therapeutics for pediatric AML

▪ training in mass cytometry, single cell genomics analysis, droplet digital PCR, multi-color flow cytometry, xenograft modeling, colony assays

Active Grants:

St. Baldrick’s Foundation Fellow Grant (July 2017 – June 2020)

▪ validation of CD123 as a stem cell marker and therapeutic target in pediatric AML

▪ $92,500/year salary and fringe benefits

Swim Across America 2018 Denver chapter funds allocation (Sept 2018 - )

▪ salary and administrative support for pediatric Phase 1 clinical trial of idasanutlin and venetoclax for relapsed/refractory leukemias

Leukemia Lymphoma Society Translational Research Program Grant (July 2019 – June 2022)

▪ sub-investigator (13% salary support, direct costs)

▪ identification of surface markers for pediatric leukemia stem cells for rational design of dual antigen specific CAR-T cells

Completed Grants:

Cancer League of Colorado Cancer Research Grant (July 2017 - June 2018)

▪ validation of CD123 as a stem cell marker and therapeutic target in pediatric AML

▪ $30,000 direct costs

Bibliography:

Publications:

1. Palermo C, Bennett CA, Winters AC, Hemenway CS. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. Leukemia Res. (2008); 32(4): 633-42.

2. Bennett CA, Winters AC, Barretto NN, Hemenway CS. Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT syngergistically enhances the cytotoxic effect of established chemotherapeutic agents. Leukemia Res. (2009); 33(7): 937-47.

3. Winters AC, Friedlander P, Jaffe BM, Khalek MA, Moroz K, Kandil E. A post-menopausal woman with gross cystic disease fluid protein-15 and estrogen receptor-positive recurrence of papillary thyroid cancer. Thyroid (2010); 20(12): 1413-7.

4. Winters AC, Gore LG. “Acute Lymphoblastic Leukemia.” Chapter in Pediatrics subsection of Decision Support in Medicine, LLC (2016 update).

5. Winters AC, Bernt KM. MLL-rearranged leukemias – an update on science and clinical approaches. Frontiers in Pediatrics (2017);5:4. doi: 10.3389/fped.2017.00004. eCollection 2017.

6. Palao MA, Winters A, Liang X, Nuss R, Niermeyer S, Gossling M, Wright C. Vitamin K deficiency presenting in an infant with an anterior mediastinal mass: a case report and review of the literature. Case Reports in Pediatrics (2017);2017:7628946. doi: 10.1155/2017/7628946.

7. Winters AC, Black JO, Cost CR. Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1. Pediatric Blood & Cancer (2017);64(12). doi: 10.1002/pbc.26643.

8. Stevens B, Khan N, D’Alessandro A, Nemkov T, Winters A, Jones C, Zhang W, Pollyea D, Jordan C. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nat Comm (2018);9(1):3694-3708.

9. Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, Colgan SP, Jordan CT. Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells. Cancer Cell (2018);34(4):659-673.

10. Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in acute myeloid leukemia patients. Nat Med (2018);24(12):1859-1866.

11. Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: clinical results and predictive modeling using computational analysis. Leuk Res (2019);81:43-49.

12. Stevens BM, Zhang W, Pollyea D, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T cell therapy for the eradication of myelodysplastic syndrome stem cells. Exp Hematol (2019); 74:52-63.

13. Winters A, Gutman J, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky J, Rosser J, Ewalt M, Seigele B, Rana V, Schuster S, Abbott D, Stevens B, Jordan C, Smith C, Pollyea D. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv (2019) [accepted for publication].

14. Winters A, Gore L. Moving immunotherapy into the frontline in ALL. Hematology, The Education Program (2019) [accepted for publication].

Posters:

1. Winters AC, Palermo C, Bennett C, Hemenway CS. The anti-leukemic peptide PFWT induces necrotic cell death in MV4-11 leukemia cells (poster). Annual M.D./Ph.D. Student Conference, Keystone, CO, July 2007.

2. Winters AC, Kethman W, Kruse-Jarres R, Washko JK. Vitamin D insufficiency in pediatric sickle cell patients correlates with age and with reticulocytosis but not with frequency of hospitalizations (poster). Presented at the 5th Annual Sickle Cell Disease Research and Educational Symposium and Scientific Meeting, Hollywood, FL, February 2011.

3. Winters AC, Kethman W, Kruse-Jarres R, Washko JK. Vitamin D insufficiency in pediatric sickle cell patients correlates with age, genotype, and reticulocytosis and not with frequency of hospitalizations (poster). Presented at the Annual Meeting of the Pediatric Academic Societies, Denver, CO, May 1, 2011.

4. Winters AC, Chute C, Hammill A, Elluru R, Dasgupta R, Dickie B, Wentzel M, Adams D. Twice daily dosing of propranolol for treatment of infantile hemangiomas is safe and effective (poster). Presented at the 2014 ASPHO Annual Meeting, May 2014.

5. Winters AC, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-associated mutations via droplet digital PCR Is predictive of outcomes post-transplant. Presented at the American Society of Hematology Annual Meeting, San Diego, CA, December 1, 2018.

Invited Presentations:

1. “Venetoclax/idasanutlin combination study in pediatric acute leukemias.” ALL Breakout Session on New Agents, Children’s Oncology Group Fall Meeting, October 3, 2018.

2. “Identifying new therapies for pediatric AML.” Colorado State University Developmental Therapeutics / Tumor Host Interactions Retreat, October 23, 2018.

Teaching/Mentorship Record:

2015-2017 monthly educational lecture to rotating Hem/Onc residents (Transfusion Med 101)

2016 nursing advanced education session lecture, Chimeric Antigen Receptor T-Cells

2016-2017 enrolled in the Teaching Certificate Program (TCP), University of Colorado Denver

(1-year program to enhance clinical teaching skills)

2016-curr small group preceptor for Blood and Lymph problem-based learning (medical students)

2016-curr preparation and delivery of Pediatric Hematology/Oncology board review lectures to

PGY4-6 fellows (CML and Myeloproliferative Diseases, Acute Myeloid Leukemia,

Molecular Biology of Oncogenesis)

2018 preparation of case-based learning for pediatric residents (Transfusion Medicine)

2018 - faculty mentor to pediatric hematology/oncology fellow (Dr. Natalie Macaruso)

2019 - Scholarship Oversight Committee member for pediatric hematology/oncology fellow (Dr. Zach Graff)

2019 - Associate Program Director, Pediatric Hematology/Oncology Fellowship

Service, QI, and Other Activities:

2018-curr Ad hoc grant reviewer for St. Baldrick’s Foundation (spring grant cycle)

2018-curr Member of University of Colorado Cancer Center Scientific Review Committee / Protocol

Review and Monitoring System (meets monthly)

2018-curr Ad hoc abstract reviewer for American Society of Hematology Annual Meeting

2018-curr Member of Safe Handoff QI team at Children’s Hospital Colorado (meets monthly)

2019-curr Member of Iron Overload QI team at Children’s Hospital Colorado (meets monthly)

References:

Lia Gore, M.D.

Chief, Pediatric Hematology/Oncology/Bone Marrow Transplant

The Robert J. and Kathleen A. Clark and Ergen Family Endowed Chairs

Children's Hospital Colorado | Center for Cancer and Blood Disorders

13123 East 16th Avenue, Box B115, Aurora CO 80045

Phone: (720) 777-6458

Fax: (720) 777-7339

E-mail: lia.gore@ucdenver.edu

Carrye Cost, M.D.

Assistant Professor, Pediatrics

Center for Cancer and Blood Disorders | Children’s Hospital Colorado

13123 East 16th Avenue, Box 115, Aurora, CO 80045

Phone: (720) 777-6775

Fax: (720) 777-7226

E-mail: carrye.cost@

Tim Garrington, M.D.

Associate Professor, Pediatrics and Director, Ped Hem-Onc Fellowship Program

Center for Cancer and Blood Disorders I Children’s Hospital Colorado

13123 East 16th Avenue, B-115, Aurora, CO 80045

Phone: (720) 777-8365

Fax (720) 777-7279

E-mail: timothy.garrington@

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download